Protalix BioTherapeutics Other Current Liabilities

Protalix BioTherapeutics (PLX) currently reports a other current liabilities of $22M as of March 2026. That compares with $23M in the prior-year period — down 5.4% year over year. Use the charts on this page to explore Protalix BioTherapeutics's other current liabilities history and peer comparisons.

Protalix BioTherapeutics's other current liabilities decreased from $23M to $22M — a 5.4% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Protalix BioTherapeutics reported $22M in other current liabilities as of March 2026. That compares with $23M in the prior-year period — down 5.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $22M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Protalix BioTherapeutics, and consider following PLX for alerts when major investors trade the stock.

Protalix BioTherapeutics is classified in the Healthcare sector. On other current liabilities, it currently shows $22M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PLX with unrelated industries.